Becton, Dickinson and Company

598 articles with Becton, Dickinson and Company

• Vulnerabilities Disclosed by CyberMDX Allow Attackers to Take Over Infusion Pumps

  6/13/2019

  Vulnerabilities found in BD Alaris Gateway Workstation affirmed by ICS-CERT with CVSS scores of 10.0 and 7.3 respectively

• BD Announces Early Tender Results - June 3, 2019

  6/4/2019

  Becton, Dickinson and Company announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority set forth in the table below, up to the applicable Tender SubCap, if any, of each of the Company's 5.000% Notes due 2040, 4.875% Notes due 2044, 4.685% Notes due 2044, 3.700% Notes due 2027, 3.734% Notes due 2024, 4.669% Notes due 2047 and 2.894% Notes due 2022

• Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities - May 20, 2019

  5/20/2019

  Becton, Dickinson and Company announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below.

• BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance

  5/9/2019

  The company reaffirmed its full fiscal year 2019 comparable, currency-neutral revenue guidance, and updated its adjusted diluted earnings per share guidance.

• BD to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

  5/1/2019

  BD announced that it will present at the Bank of America Merrill Lynch 2019 Global Healthcare Conference on Tuesday, May 14, 2019, at 10:00 a.m. ET.

• BD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation

  4/30/2019

  New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.

• BD Board Declares Dividends, payable on June 28, 2019

  4/29/2019

  The Board of Directors of BD has declared a quarterly dividend of $0.77 per common share, payable on June 28, 2019 to holders of record on June 7, 2019.

• BD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion

  4/8/2019

  BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testing

• BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call

  4/4/2019

  BD announced that it will conduct a live webcast of its second fiscal quarter 2019 earnings conference call on Thursday, May 9, 2019, at 8:00 a.m..

• BD Launches New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification

  3/26/2019

  BD FACSDuet™ system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric™ clinical flow cytometer

• BD Statement on Paclitaxel-Coated Devices

  3/21/2019

  BD, a leading global medical technology company, issued the following statement related to the recent letter from FDA to health care providers regarding paclitaxel-coated devices:

• BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

  3/14/2019

  Venovo™ Venous Stent proven safe and effective in iliac and femoral veins

• VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD

  3/9/2019

  VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.

• BD to Present at the Barclays Global Healthcare Conference

  3/4/2019

  BD, a leading global medical technology company, announced that it will present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2019, at 2:05 p.m. ET.

• BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

  2/5/2019

  As reported, revenues of $4.160 billion increased 35.1 percent.

• BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique

  1/24/2019

  BD Nano™ Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration

• BD Board Declares Dividends Payable on March 29, 2019

  1/22/2019

  The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on March 29, 2019 to holders of record on March 8, 2019. 

• BD Announces Preliminary Results For 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

  1/17/2019

  - Preliminary reported revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, preliminary revenues increased 5.2 percent. - As reported, preliminary diluted earnings per share of $2.05 increased 369.7 percent. - As adjusted, preliminary diluted earnings per share of $2.70 increased 8.9 percent, or 14.9 percent on a currency-neutral basis. - The company reaffirms previously issued fiscal year 2019 revenue and adjusted

• BD Announces Webcast of Annual Meeting of Shareholders on January 22, 2019

  1/16/2019

  BD (Becton, Dickinson and Company) announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 22, 2019, at 1 p.m. (ET).

• BD Announces Live Webcast Of First Fiscal Quarter 2019 Earnings Conference Call

  1/8/2019

  BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference call on Tuesday, February 5, 2019, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.